Get the Stockscreener App
104.77
0.09%
0.09
After Hours:
104.89
0.12
+0.11%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $104.77, with a volume of 6.29M.
It is up +0.09% in the last 24 hours and up +2.35% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$104.68
Open:
$105.65
24h Volume:
6.29M
Relative Volume:
0.64
Market Cap:
$181.29B
Revenue:
$46.59B
Net Income/Loss:
$5.41B
P/E Ratio:
33.86
EPS:
3.0938
Net Cash Flow:
$7.38B
1W Performance:
+5.19%
1M Performance:
+2.35%
6M Performance:
+9.74%
1Y Performance:
-17.91%
1-Day Range:
$104.19
$105.88
1-Week Range:
$99.78
$105.88
52-Week Range:
$81.97
$132.03
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
104.77 | 181.29B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.78 | 121.24B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.38 | 112.92B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.34 | 64.25B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.53 | 49.88B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-26 | Initiated | Barclays | Overweight |
| Oct-02-26 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-13-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-01-26 | Initiated | Robert W. Baird | Outperform |
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
StoneX reiterates Buy on Abbott Labs stock ahead of earnings By Investing.com - Investing.com India
Abbott Laboratories stock: TD Cowen sets a USD 135.00 target for Abbott Laboratories stock - ad-hoc-news.de
TD Cowen on Abbott Labs (ABT): 'The Stage is Set for a Stronger 2H' - StreetInsider
Reasons to Add STE Stock to Your Portfolio Right Now - Zacks Investment Research
Haemonetics Gains 149.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Is it Apt to Retain Medtronic Stock in Your Portfolio Now? - Zacks Investment Research
Pregnancy Tests Recalled Globally Over False Positives - Gizmodo
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? - Zacks Investment Research
Abbott Laboratories To Go Ex-Dividend On October 15th, 2026 With 0.63 USD Dividend Per Share - Moomoo
Abbott Laboratories stock may move 4.7% on earnings release - Investing.com
Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research
Medtronic Pays More Today. Abbott Raises Its Dividend Faster. Which Stock Wins? - 24/7 Wall St.
SimpleScreen CRC Launch Could Be A Big Moment For Abbott Stock - Simply Wall Street
Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings? - TradingView
Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell - The Motley Fool
Abbott (ABT) Gains As Market Dips: What You Should Know - Zacks Investment Research
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott Laboratories (NYSE:ABT): A Quality Stock With Durable Fundamentals - ChartMill
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 - GlobeNewswire Inc.
Abbott Laboratories is More than a Dividend Stock. Here’s Why. - Yahoo Finance
What Is Abbott Laboratories (ABT) Telling Investors With Its New Product Push? - Simply Wall Street
Lake County-based Abbott to pay nearly $385 million over claims it made baby formula in leaky, unsanitary plant - Lake and McHenry County Scanner
Abbott Laboratories (ABT) Debuts Ensure Max Protein Powder With Creatine And HMB - Yahoo Finance
History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio. - The Motley Fool
Abbott (ABT) Stock Could Be 24% Overvalued After Heart Failure News - Yahoo Finance
Abbott Laboratories (ABT), Why Is Fresh Attention Building Around It? - Simply Wall Street
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - Zacks Investment Research
China Adult Feeding Tubes and Formula Market Outlook to 2033Revenue, Volume, Pricing, and Company Share | Forecast Data Reveals Market Entry and Expansion Opportunities - GlobeNewswire Inc.
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Is Abbott Laboratories (ABT) a Dividend Bargain After Its 2026 Selloff? - Yahoo Finance
Abbott Laboratories Contamination Lawsuit Ends in $385 Million Settlement — But Nobody's Admitting Anything - https://www.lawnews.co.uk/
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note - Zacks Investment Research
What Will the Libre Duo Launch Mean for Abbott Laboratories (NYSE:ABT)? - Kalkine Media
Abbott Laboratories stock: FDA approves new CardioMEMS capabilities - AD HOC NEWS
Did Heart Failure Device Updates Just Shift Abbott Stock’s Investment Narrative? - Simply Wall Street
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
Better Dividend Play for Retirees: MDT or ABT? One Delivers Significantly More Yield - 24/7 Wall St.
Abbott Laboratories stock trades 26.5 percent below its yearly high - AD HOC NEWS
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown? - Zacks Investment Research
Redburn upgrades Abbott Laboratories stock to Buy - AD HOC NEWS
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Grace Groner bought three $60 shares of Abbott Laboratories in 1935 and worked there 43 years; she left more than $7 million to benefit Lake Forest College students when she died at 100 - Parade Magazine
AG Fitch announces $384M false claims settlement with Abbott Laboratories - Picayune Item
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbott Laboratories Stock (ABT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| John A. McCoy, Jr. | Officer |
Sep 02 '26 |
Proposed Sale |
109.52 |
27 |
2,957 |
0 |
| Robert B. Ford | Officer |
Aug 25 '26 |
Proposed Sale |
115.85 |
398,832 |
46,204,386 |
0 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Sale |
115.85 |
398,832 |
46,204,798 |
306,461 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Option Exercise |
54.02 |
398,832 |
21,545,946 |
705,293 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT |
Aug 11 '26 |
Sale |
109.83 |
5,850 |
642,506 |
70,724 |
| Louis H. Morrone | Officer |
Aug 11 '26 |
Proposed Sale |
109.83 |
5,850 |
642,506 |
0 |
| Robert J. Alpern | Retired Director |
May 15 '26 |
Proposed Sale |
85.25 |
7,587 |
646,791 |
0 |
| Stratton John G | Director |
May 07 '26 |
Buy |
86.82 |
2,000 |
173,640 |
23,319 |
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
| Robert J. Alpern | Retired Director |
Apr 27 '26 |
Proposed Sale |
92.55 |
29,211 |
2,703,457 |
0 |
0.70%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):